The FDA record identifies Xvivo Perfusion, Inc. as the applicant for P180014, approved April 26, 2019, covering the XPS™ with Steen Solution™ Perfusate under product code PHO. The device's generic name in the filing is a normothermic preservation system for transplantation of initially unacceptable donor lungs, and the approval order is addressed to the applicant at 3666 S. Inca Street, Englewood, Colorado. The supplied collection holds two PMA records for this applicant, both with an approval decision, and the record sample comprises those same two entries. [1][2][10]
Documented device and stated indication
The approval order describes the device as indicated for flushing and temporary continuous normothermic machine perfusion of initially unacceptable excised donor lungs, during which the ex vivo function of the lungs can be reassessed for transplantation. The FDA summary of safety and effectiveness data names the generic device as Ex Vivo Lung Perfusion (EVLP) and the trade name as the XVIVO Perfusion System (XPS™) with STEEN Solution™ Perfusate, with product code PHO. The same summary states that STEEN Solution™ is an acellular perfusate used without adding blood to the perfusion circuit. [2][5]
Approval and supplement record
P180014 was received May 10, 2018, and approved April 26, 2019, with a Federal Register notice date of May 3, 2019, and docket number 19M-2052. The later record is supplement S014, received June 18, 2026, and approved September 16, 2026, under the real-time process supplement type with reason listed as change design/components/specifications/material. Its approval order statement covers a supplier and material change to the luer caps of the lung cannula set. [1][2]
The FDA PMA page for P180014 lists supplements S001, S003 through S014, and notes that the device has supplements and that the device description, function or indication may have changed, directing readers to the supplements for current information. The page's last-updated date is October 26, 2026. [3]
Labeling and post-approval materials
The XPS™ Instructions for Use, document 9182-0189 Revision U issued 2025-02, covers software version 5.3.x and hardware version 1.9, restricts use to qualified medical professionals trained in the technique and surgical procedure, and refers readers to the accompanying professional labeling booklet for post-market clinical studies and related safety information. The document is published by XVIVO Perfusion AB, Entreprenörsstråket 10, Mölndal, Sweden, and states that XVIVO trademarks are registered trademarks of that company. [6]
The FDA summary of safety and effectiveness data records that the centrifugal pump head used during EVLP is the MAQUET Rotaflow, previously cleared under K991864, and that sterilization testing used a validated SAL 10-6 ethylene oxide cycle. The FDA post-approval studies database page describes the agency's authority to require post-approval studies; the public information does not state the status or results of any study for this device. [5][8]
Applicant identity and scope of the record
The applicant name on the FDA filings is Xvivo Perfusion, Inc., with the Englewood, Colorado address appearing as the applicant's filing address in the approval order and PMA records. The Instructions for Use identifies XVIVO Perfusion AB in Sweden as the publisher of that document and owner of the XVIVO trademarks; the public documents do not state a corporate relationship between the two entities, so any parent or brand link beyond that is unknown. The two-record collection reflects the supplied filings as of the snapshot date and is not a measure of total portfolio, sales or safety performance. [1][2][6][10]
